Lamark Biotech Pvt Ltd.

Lamark Biotech Pvt Ltd. , an innovative firm based in India, focuses on developing oral therapies aimed at enhancing metabolic health and addressing health challenges like obesity and diabetes through advanced therapeutic solutions. Founded in 2018, Lamark Biotech Pvt Ltd. operates from Pune, India, specializing in metabolic health therapies.

The company recently secured INR 65 million in funding led by Indian Angel Network. The founder's previous entrepreneurial experience is not detailed publicly. Lamark has raised a total of INR 65 million across its funding rounds, with the latest funding round occurring on July 1, 2025, which is also the total amount raised to date, targeting advancements in their product offerings and market reach. Syntis Bio specializes in the development of oral therapies designed to leverage the unique biology of the small intestine, aiming to optimize metabolic health and address a range of health challenges, including obesity, diabetes, and rare genetic disorders.

Their core products include a pipeline of drug candidates, with a primary focus on obesity treatment, reflecting the company's commitment to innovating therapeutic solutions that promise effectiveness and sustainability. These therapies are designed to enhance drug absorption and metabolic control, catering to patients who require advanced treatment options for chronic conditions. Syntis Bio's products are targeted towards both individual patients and healthcare providers across diverse geographical markets, including Europe and North America, thereby addressing a global demand for improved therapeutic interventions. Syntis Bio generates revenue through partnerships with healthcare providers and research institutions, aiming to bring their innovative therapies to market.

The company's revenue structure is built around collaboration agreements and licensing deals, where pharmaceutical companies or healthcare systems may acquire rights to develop and distribute Syntis's flagship products. Transactions are expected to involve direct-to-consumer sales models, especially for their oral therapies, which may also be made available through healthcare networks and specialty pharmacies. While specific pricing plans for their products are not disclosed, the revenue model reflects a strategic approach to addressing healthcare needs through comprehensive therapeutic solutions, ultimately positioning Syntis Bio as a key player in the treatment of metabolic disorders. In June 2025, Lamark Biotech Pvt Ltd.

raised INR 65 million in pre-Series A funding led by the Indian Angel Network, with participation from BioAngels. The company plans to utilize the funding to scale production capacity, execute commercial deployment of turbine heat pump technology, and strengthen its market presence across the residential heating sector. Looking ahead, Lamark aims to expand its market presence into new regions, including Europe and North America, by 2026, while also launching new products designed to enhance metabolic health.